Loading
Independent bodies that judge whether a new cancer drug's benefit is worth its price; decisive for coverage outside the US and increasingly inside it.
The Institute for Clinical and Economic Review (US, non-governmental) publishes cost-effectiveness reports and 'fair price' benchmarks; NICE (England), CADTH/CDA (Canada), G-BA/IQWiG (Germany), HAS (France), and PBAC (Australia) formally gate reimbursement. Thresholds of $100,000-150,000 per QALY (ICER) or £25,000-35,000 (NICE, since 2 April 2026) versus oncology prices above $200,000 per year drive negotiations and delays.
Shares AMNOG (Germany, 2011), EU HTA Regulation (EU) 2021/2282: joint clinical assessments, Health technology assessment (HTA), reimbursement and QALYs.
Shares Medicare coverage with evidence development, AMNOG (Germany, 2011), EU HTA Regulation (EU) 2021/2282: joint clinical assessments, Health technology assessment (HTA), reimbursement and QALYs.
Shares NICE technology appraisal methods (2022), Health technology assessment (HTA), reimbursement and QALYs.
Shares Medicare coverage with evidence development, Health technology assessment (HTA), reimbursement and QALYs.
Shares AMNOG (Germany, 2011), Health technology assessment (HTA), reimbursement and QALYs.
Shares AMNOG (Germany, 2011), Health technology assessment (HTA), reimbursement and QALYs.
Shares Medicare coverage with evidence development, Health technology assessment (HTA), reimbursement and QALYs.
Shares NICE technology appraisal methods (2022), Health technology assessment (HTA), reimbursement and QALYs.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/